Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study
Journal of Alzheimer’s Disease · 2025-09 · 107 (2) · 806-818
DOI: 10.1177/13872877251362496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025-09. Verfasst von Deming Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Nervous System Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Increased glial fibrillary acidic protein (GFAP) in blood, a biomarker of reactive astrogliosis and astrocytic injury, was observed in a variety of neurological disorders. However, the causal relationship between plasma GFAP and neurological disorders remains unclear.
Objective
We aim to investigate causal association between plasma GFAP levels and neurological disorders using bidirectional Mendelian randomization (MR).
Methods
The genome-wide association studies for neurological disorders, including neurodegenerative diseases, neuroimmune disorders, cerebrovascular diseases, and epilepsy, were collected. Genetic variables associated with plasma GFAP levels were obtained from the UK Biobank Pharma Proteomics Project. Inverse variance weighted or Wald ratio method was used as the main analysis to assess the causal association.
Results
Genetically predicted higher plasma GFAP levels were found to be associated with an increased risk of encephalitis (odds ratio [OR] = 2.52; 95% confidence interval [CI] = 1.67–3.47; p = 1.22 × 10 –5 ). Furthermore, we found that Alzheimer's disease (β = 0.05; standard error [SE] = 0.01; p = 6.63 × 10 –8 ), frontotemporal dementia (β = 0.12; SE = 0.01; p = 5.10 × 10 –16 ), and dementia with Lewy bodies (β = 0.08; SE = 0.02; p = 5.45 × 10 –5 ) were causally linked to an increase in plasma GFAP levels. Even after controlling for the influence of aging, these associations remained significant.
Conclusions
Our study found that higher plasma GFAP levels may increase the risk of encephalitis, while neurodegenerative dementia may enhance the plasma GFAP levels, supporting the clinical utility of blood GFAP as a reliable biomarker in neurological diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Deming Jiang, Min Chu, Liyong Wu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jiang, D., Yue, A., Nan, H., Hou, J., Chu, M., Wang, Y., & Wu, L. (2025). Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study. Journal of Alzheimer’s Disease, 107(2), 806-818. https://doi.org/10.1177/13872877251362496
Vancouver
Jiang D, Yue A, Nan H, Hou J, Chu M, Wang Y, et al. Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study. Journal of Alzheimer’s Disease. 2025;107(2):806-818. doi:10.1177/13872877251362496
BibTeX
@article{Jiang2025,
author = {Jiang, Deming and Yue, Ailing and Nan, Haitian and Hou, Jiahui and Chu, Min and Wang, Yihao and Wu, Liyong},
title = {Plasma glial fibrillary acidic protein and neurological diseases: A bidirectional Mendelian randomization study},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
volume = {107},
number = {2},
pages = {806--818},
doi = {10.1177/13872877251362496}
}
EUVIMED